IL6R and rheumatoid arthritis: Tocilizumab, a humanized anti–IL-6R mAb that blocks both soluble IL-6R and membrane-bound IL-6R, has been approved by the FDA for the treatment of RA and shown to be an effective therapy for other inflammatory diseases, including Castleman's disease [13].